🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Bellicum Pharmaceuticals clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our USA and Italy registers with Bellicum Pharmaceuticals as lead sponsor. Synced 27 Sep 2026
4Current trials
0Recruiting now
2Drugs in these trials
2Trial registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Bellicum Pharmaceuticals is the lead sponsor of 4 current clinical trials in our USA and Italy registers. None of its ClinicalTrials.gov trials is recruiting at the moment. The most common phase is Phase 1. The drugs named most often in its trials are Rimiducid and Rivogenlecleucel. The most-studied condition is Myelodysplastic Syndromes.

ClinicalTrials.gov trials by status

  • Active, closed4100%

Trials by phase

  • Phase 1250%
  • Phase 1/2250%
01

Clinical trials sponsored by Bellicum Pharmaceuticals

4 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant
NCT02477878 · Leukemia, Myelodysplastic Syndromes, Lymphoma
Drug: Rimiducid
Phase 1 Active, closed 2016-07 USA
Safety/PK Study of Gene Modified Donor T Cell Infusion in Children With Recurrent Hem Malignancies After Allo Transplant
NCT03459170 · ClinicalTrials.gov ↗ · Hematologic Malignancy
Phase 1 Active, closed 2018-02 Italy
Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant
NCT03301168 · ClinicalTrials.gov ↗ · Acute Lymphoblastic Leukemia, Leukemia, Acute Myeloid (AML), Child, Lymphoma, Non-Hodgkin
Phase 1/2 Active, closed 2014-04 USA
Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant
NCT01744223 · ClinicalTrials.gov ↗ · Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Lymphoma
Drug: Rimiducid
Phase 1/2 Active, closed 2013-03 USA

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Bellicum Pharmaceuticals trials

2 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Bellicum Pharmaceuticals trials

9 conditions
04

By trial register

RegisterTrialsRecruiting
Clinical trials in USA30
Clinical trials in Italy10

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Myelodysplastic Syndromes

SponsorTrials
Peking University People's Hospital5
Groupe Francophone des Myelodysplasies5
Taiho Oncology4
Orca Biosystems3
Minovia Therapeutics2
Geron Corporation1
Kind Pharmaceuticals1
Treadwell Therapeutics1
University Hospital Freiburg1
GCP-Service International West1

Sponsors with the most current trials registered for this condition.

06

Questions about Bellicum Pharmaceuticals trials

How many clinical trials does Bellicum Pharmaceuticals sponsor?

Bellicum Pharmaceuticals is the lead sponsor of 4 current trials on ClinicalTrials.gov in our USA and Italy registers, as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.

Are Bellicum Pharmaceuticals trials recruiting?

Not at the moment. None of its 4 ClinicalTrials.gov trials is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.

Which drugs is Bellicum Pharmaceuticals testing?

Its current trials name 2 drugs and biologicals as interventions. The most frequent are Rimiducid (4) and Rivogenlecleucel (2). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 27 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.